#319 Should a ‘flozin’ be chosen? Part 2: SGLT2 inhibitors in patients with chronic kidney disease
CLINICAL QUESTION
What are the effects of sodium-glucose cotransporter 2 inhibitors (SGLT2i) on patient-relevant outcomes in chronic kidney disease (CKD)?
BOTTOM LINE
For every 100 patients with CKD treated with an SGLT2i for 5 years, ~3-4 fewer will develop end-stage kidney disease (ESKD) and ~3-4 fewer will die from any cause compared to placebo. Sotagliflozin is not better than placebo for these outcomes
Reading Tools for Practice Article can earn you MainPro+ Credits
Join NowAlready a CFPCLearn Member? Log in
EVIDENCE
- Two systematic reviews of relevant randomized, placebo-controlled trials (RCTs) included patients with CKD.1,2 Results statistically different unless noted.
- 52,827 patients with various cardiovascular/CKD risk. Of those with CKD, at 5 years:1
- ESKD: 8.9% versus 12% (placebo), number needed to treat (NNT)=33.
- Cardiovascular death: 11% versus 14% (placebo), NNT=27.
- Overall mortality: 19% versus 22% (placebo), NNT=31.
- 8 RCTs, 26,106 patients with baseline CKD, at 2.5 yrs:2
- Cardiovascular disease: 10% versus 11% (placebo), NNT=91.
- Composite kidney outcome (40-60% eGFR decline, ESKD, or renal death): 4.8% versus 6.9% (placebo), NNT=48.
- Limitations: Included RCTs not specific to CKD patients.
- 52,827 patients with various cardiovascular/CKD risk. Of those with CKD, at 5 years:1
- Three industry-funded RCTs3,4,5 specific to CKD patients (neither above review included all 3 in every outcome). Mean eGFR~40-55ml/min/1.73m2, albumin-to-creatinine ratio ~75-105mg/mmol, 67-100% had diabetes.
- CREDENCE:3 4,401 patients, canagliflozin 100mg daily. At 2.6 years:
- ESKD: 5.3% versus 7.5% (placebo), NNT=45.
- Cardiovascular death: 5.0% versus 6.4% (placebo), NNT=71.
- All-cause mortality: 7.6% versus 9.1% (placebo), NNT=67.
- DAPA-CKD:4 4,304 patients, dapagliflozin 10mg daily. At 2.4 years:
- ESKD: 5.1% versus 7.5% (placebo), NNT=42.
- Cardiovascular death: 3.0% versus 3.7% (placebo), not statistically different.
- All-cause mortality: 4.7% versus 6.8% (placebo), NNT=48.
- SCORED:5 10,584 patients, sotagliflozin 200-400mg daily. At 1.3 years:
- No difference in composite kidney outcome, cardiovascular death, or all-cause mortality.
- Adverse events:3-5
- Increase in genital infections [number needed to harm (NNH) 59-67], volume depletion (NNH=59-77), and DKA (NNH=220 to not statistically significant).
- CREDENCE:3 4,401 patients, canagliflozin 100mg daily. At 2.6 years:
- One meta-analysis of DAPA-CKD and CREDENCE only. At ~2.5 years:6
- ESKD: 5.2% versus 7.5% (placebo).
- Cardiovascular death: 4% versus 5% (placebo).
- EMPA-KIDNEY trial stopped early for benefit.7,8
- Guidelines9 recommend metformin and SGLT2i first-line for patients with type-2 diabetes and CKD.
- Cost: ~$90/month.10
Latest Tools for Practice
#378 Tony Romo-sozumab: Winning touchdown in osteoporosis or interception for the loss?
What is the efficacy and safety of romosozumab in postmenopausal women with osteoporosis?
#377 How to slow the flow IV: Combined oral contraceptives
In premenopausal heavy menstrual bleeding due to benign etiology, do combined oral contraceptives (COC) improve patient outcomes?
#376 Testosterone supplementation for cis-gender men: Let’s (andro-)pause for a moment (Update)
What are the benefits and harms of testosterone supplementation in healthy cis-gender men or those with age-related low testosterone?
SGLT2i meds appear beneficial in CKD